Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 3, 2011, Pages 206-210

  Jeske, Walter P ^a,c   Walenga, Jeanine M ^a   Samama, Meyer M ^b   Hoppensteadt, Debra ^a   Mayuga, Myttle ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HÔTEL DIEU   (France)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antifactor Xa activity; antithrombin; antithrombotic activity; fondaparinux; heparin pentasaccharide

Indexed keywords

ANTIFACTOR XA; ANTITHROMBIN; FONDAPARINUX; PROTEIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG POTENCY; HUMAN; LIVER DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTICOAGULANTS; ANTITHROMBIN PROTEINS; FACTOR XA; HUMANS; LIVER DISEASES; POLYSACCHARIDES; RABBITS; THROMBOSIS;

EID: 79955059072     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328343f859     Document Type: Article

References (23)

1. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants. Chest 2008; 133:141S-159S.
2. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J, Samama MM. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Exp Opin Investig Drugs 2002; 11:397-407. (Pubitemid 34213393)
3. Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50:1742-1751. (Pubitemid 47600591)
4. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger C, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464-1476.
5. Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature 1991; 350 (Suppl):30-33.
6. van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 1993; 32:1671-1690.
7. Herbert JM, Petitou M, Lormeau JC. SR90107A/ORG31540, a novel antifactor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15:1-26. (Pubitemid 27326353)
8. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIIImediated neutralization of factor Xa. Thromb Haemost 1995; 74:1474-1477. (Pubitemid 26018664)
9. Torri G, Casu B, Gatti G, Petitou M, Choay J, Jacquinet JC, Sinay P. Monoand bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue. Biochem Biophys Res Commun 1985; 128:134-140. (Pubitemid 16235142)
10. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86:1-36. (Pubitemid 27272341)
11. Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J, et al. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole antifactor Xa activity. Thromb Res 1988; 51:23-33.
12. Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis, and treatment options. Drugs 2007; 67:1429-1440. (Pubitemid 47026392)
13. Walenga JM, Fareed J, Messmore HL. Newer avenues in the monitoring of antithrombotic therapy. Semin Thromb Hemost 1983; 9:346-354.
14. Fareed J, Walenga JM, Kumar A, Rock A. A modified stasis-thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost 1985; 11:155-175. (Pubitemid 15057128)
15. Parma B, Bergonzini GL, Bianchini P, Osima B. Antithrombotic activity of heparin and low molecular weight heparin in animals treated with anti-ATIII antibodies. Thromb Haemorrhagic Disord 1991; 3:13-15.
16. Walenga JM, Bara L, Hoppensteadt DA, Choay J, Fareed J, Samama M, et al. ATIII as a rate-limiting factor for the measurement of pentasaccharide in laboratory assays. Thromb Haemost 1991; 65:2246.
17. Walenga JM, Hoppensteadt DA, Mayuga M, Samama MM, Fareed J. Functionality of pentasaccharide depends on endogenous antithrombin levels. Blood 2000; 96:817a.
18. Dempfle CE, Eichner J, Suvajac N, Ahmad-Nejad P, Neumaier M, Borggrefe M. The reduced anticoagulant effect of fondaparinux at low antithrombin levels. Anesth Analg 2009; 109:712-716.
19. Conrad J, Brosstad F, Lie Larson M, Samama M, Abildgaard U. Molar antithrombin concentration in normal human plasma. Haemostasis 1983; 13:363-368. (Pubitemid 14152590)
20. Montalescot G, Walenga JM. Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. Clin Appl Thromb Hemost 2009; 15:183-196.
21. Notrthup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101:1524-1528. (Pubitemid 43980626)
22. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104:96-101.
23. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, et al. An imbalance of pro- vs. anticoagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137:2105-2111.